Furosemide, a loop diuretic, is used to increase urine output in patients with acute kidney injury (AKI). It remains uncertain whether the benefits of furosemide in AKI outweigh its potential harms. We investigated if furosemide influenced oxidative stress in 30 critically ill patients with AKI by measuring changes in F 2 -isoprostanes (F 2 -IsoPs), markers of in-vivo oxidative stress, in plasma and urine following intravenous furosemide. Urine F 2 -IsoPs were higher in sepsis (p=0.001) and increased in proportion to urine furosemide (p=0.001). The furosemide-induced increase in urine F 2 -IsoPs differed depending on AKI severity (p<0.001), and was greatest in those with the most severe AKI. Furosemide had no effect on plasma F 2 -IsoPs. We demonstrate for the first time that furosemide increases renal oxidative stress in AKI, and find that patients with the most severe AKI -to whom the largest doses are likely to be administered -showed the greatest increase in oxidative stress. These findings lead to the hypothesis that the common practice of administering high-dose furosemide to convert oliguric to non-oliguric AKI may induce harmful oxidative stress in the kidneys, and an adequately powered randomized controlled trial is required to determine if clinical benefits of this dosing strategy justify its potential harms. 
Introduction
The incidence of acute kidney injury (AKI), which occurs in up to ~20% of hospital and ~50% of intensive care unit patients, is rising. Treatment strategies for patients with AKI focus on several key principles (5): correction of reversible precipitants, optimal supportive care to prevent further deterioration and facilitate recovery, and the treatment of complications. Notable for its absence in this list are specific treatments targeting the kidney injury itself, as none have been demonstrated to be effective. Diuretics are commonly used in AKI in an attempt to increase urine output and convert oliguric to non-oliguric AKI, as the latter is associated with a better prognosis and makes the prevention and treatment of fluid and electrolyte complications easier.
Furosemide, the most commonly used diuretic in AKI, inhibits Na + /K + /2Cl -co-transporters (NKCC1 and NKCC2) in the ascending loop of Henle resulting in a natriuresis and diuresis.
In addition to its diuretic effect, furosemide influences renal haemodynamics and the intrarenal oxygen supply-demand relationship (3) . Protective effects of furosemide demonstrated in animal models include a reduction in the metabolic demand of medullary tubular cells due to transporter inhibition; reduced sodium transport (and therefore oxygen) requirements consequent to a reduction in glomerular filtration rate induced by renin and/or prostaglandin release; and increased renal blood flow, all of which act to improve the intra-renal oxygen supply-demand balance and decrease oxidative stress. Although total renal blood flow may be increased, furosemide has also been shown to impair intra-renal autoregulation of blood flow resulting in a detrimental change in the medullary oxygen supply-demand balance.
Human studies performed in patients with AKI have produced mixed results, with some showing benefit and others harm from the use of furosemide (3) . The overall effect of furosemide on the pathophysiology of AKI in humans remains unclear -in part, due to the 
Results
Thirty patients were recruited, with a median age of 58 years . No patients were receiving non-steroidal anti-inflammatory drugs, and only one patient was being treated with an angiotensin converting enzyme inhibitor. Inspired oxygen concentration was unchanged throughout the study in 21 patients. In the nine remaining patients, the median number of stepwise changes was 1 (IQR 1-2) and the median absolute change in inspired oxygen concentration was 10% (IQR 5-15). All plasma In univariate analysis (Table 1) 
Effect of furosemide
The final linear mixed model analyzing urine F 2 -IsoP excretion included presence of sepsis,
CrCl and plasma F 2 -IsoPs (Table 2) 
Discussion
In this study of critically ill patients with AKI and no history of chronic kidney disease or recent diuretic exposure, we demonstrate for the first time that furosemide increases levels of oxidative stress in the kidney as indicated by the increased urinary excretion of F 2 -IsoPs.
This effect was greatest in patients with the most severe AKI. There was no evidence of an increase in systemic oxidative stress following furosemide.
Urinary furosemide increased renal oxidative stress in all patients, with the greatest increase occurring in those with the most severe AKI. Although furosemide may reduce the metabolic activity of the ascending loop of Henle, an increase in renal oxidative stress could still occur through multiple other mechanisms (4) . Renal oxygen demand is highly dependent on solute transport requirements. Inhibition of solute reabsorption in the loop of Henle increases distal solute delivery, shifting the transport burden to regions of the nephron that are metabolically less efficient. As furosemide also inhibits tubuloglomerular feedback, solute transport requirements will be increased by greater nephron blood flow (and therefore filtration) and renin release will be stimulated which may further increase oxidative stress. Finally, the medullary oxygen supply-demand imbalance may be compromised by the ability of furosemide to alter the distribution of blood flow within the kidney (eg. medullary vasoconstriction), which may exacerbate any regional hypoperfusion already present due to the AKI.
Our finding that patients with the most severe AKI had the greatest increase in renal oxidative stress following furosemide is somewhat unexpected as this group of patients has the greatest pharmacodynamic limitation (7), but could be explained by these patients having the least 'reserve' available to deal with increased metabolic demand and changes in intra-renal blood flow. For example, tubular sodium reabsorption in AKI is known to be less efficient due to impaired transporter polarization and tight junction integrity, and these changes would likely be most pronounced in those with more severe AKI. The greater sensitivity of macula densa Na-K-Cl cotransporter 2 (NKCC2) to furosemide compared with loop of Henle (2) 
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The increase in renal oxidative stress following furosemide has important implications for future research on the management of AKI. An adequately powered randomized controlled trial evaluating the common practice of administering high-dose furosemide to patients with AKI is required to justify inducing potentially harmful renal oxidative stress, as furosemide has not been shown to improve patient-centered outcomes. This is especially important for patients with severe AKI in whom we found the greatest increase in urine F 2 -IsoPs per unit urine furosemide excretion, as high doses of furosemide are often required to induce diuresis as a result of pharmacodynamic and pharmacokinetic limitations to the diuretic effect of furosemide in severe AKI implying that to achieve an effective diuresis higher urine furosemide concentrations may be required (7) . The increase in renal oxidative stress following furosemide cautions against using furosemide in an attempt to improve or prevent progression of AKI, and is consistent with AKI clinical practice guidelines recommendations (5) . In view of the relationship between urine furosemide and renal oxidative stress, furosemide infusions may be preferable to repeated bolus doses as they have been shown to achieve greater diuresis with lower total furosemide excretion (3), although this requires further investigation.
A number of limitations of the present study must be acknowledged. Although an increase in urine F 2 -IsoP excretion was observed and indicates an increase in renal oxidative stress, this study was not designed to assess the effects of this oxidative stress on renal or patientcentered outcomes. However, F 2 -IsoPs are potent renal vasoconstrictors (6) and levels correlate with the development of AKI in sepsis and cardiac surgery patients (1,9). The absence of a control group in this study precludes comment on whether the increase in urine F 2 -IsoPs is a 'normal' or pathological response to furosemide.
In summary, we have demonstrated the effect of a single intravenous dose of furosemide to increase renal oxidative stress in patients with AKI. This effect was greatest in patients with the most severe AKI, to whom the largest doses of furosemide are often administered.
Clinicians must be cognizant of these findings when treating patients with AKI, although further investigation into patient-centered outcomes associated with the increase in oxidative stress is warranted.
Innovation:
Furosemide is often used to increase urine output in patients with acute kidney injury (AKI), but it remains uncertain if its benefits outweigh potential harms. We demonstrate furosemide increases renal oxidative stress in AKI, and find that patients with the most severe AKI showed the greatest increase in oxidative stress. These findings have important implications for future research on the management of AKI: the clinical benefits of the common practice of administering high-dose furosemide to convert oliguric to non-oliguric AKI should be confirmed by an adequately powered randomized controlled trial to justify inducing potentially harmful oxidative stress in the kidneys.
Notes
This study was performed as a sub-study of a recently published investigation into furosemide pharmacokinetics/pharmacodynamics in AKI (7). Briefly, 30 critically ill patients with AKI according to the Acute Kidney Injury Network (AKIN) criteria (5) gas chromatograph coupled to a Agilent 5975B mass spectrometer; Agilent, California, USA) using electron capture negative ionization and selective ion monitoring, as previously described (8) .
Statistical analysis
Correlation between baseline plasma and urine F 2 -IsoPs was assessed using Pearson's correlation coefficient after log-transformation to a normal distribution. As visual inspection of the scatterplot suggested an effect of creatinine clearance, this was tested using linear regression of plasma on urine F 2 -IsoPs with block-wise forced entry of creatinine clearance followed by the interaction term 'creatinine clearance X plasma F 2 -IsoP'. This interaction term was not statistically significant and therefore the semi-partial correlation was calculated between urine and plasma F 2 -IsoPs controlling for CrCl. The correlation between urine/plasma F 2 -IsoPs and C-reactive protein / Sequential Organ Failure Assessment (SOFA) score was calculated using Pearson's correlation coefficient after log-transformation to a normal distribution. Univariate analysis of baseline variables was performed using MannWhitney U and Kruskal-Wallis tests.
Linear mixed model analysis was used to identify factors influencing plasma and urine F 2 -IsoPs (concentration and total excreted, respectively) over time. Separate models were constructed for each site of measurement, and variables were log-transformed to a normal distribution prior to analysis if required. Variables included in the initial (full) models were selected based on theoretical plausibility, and backward variable selection (using Bayesian Information Criterion) was performed to produce the reduced (parsimonious) models presented in this paper. Urine output was not included in the linear mixed model to avoid colinearity due to the strong correlation with urine furosemide excretion and creatinine clearance. Plasma furosemide concentrations were included in the linear mixed model only as a sensitivity analysis, as they were not significantly different between the study patients in our furosemide pharmacokinetics/pharmacodynamics analysis (7 
